aHUS Trial Watch 15 (Iptacopan)
Iptacopan is a complement inhibitor that it is taken orally, twice daily. It works by inhibiting Complement Factor B (CFB ).…
aHUS Project for 2022 Rare Disease Day
Rare Disease Day 2022: aHUS Alliance Global Action to mark the day with a patient-centered video that focuses on questions posed by those affected by the rare disease atypical HUS.
It’s Time to re-Define aHUS Patient Engagement
Reaching out to Bridge Current Gaps As complement research has progressed and more is understood about thrombotic microangiopathy, it’s interesting that…
Atypical HUS CAREGIVERS
Atypical HUS families emphasize and embody the ‘care’ portion of the word ‘caregiver’. Many of those caring for someone with atypical…
TMA: the Need for a Multidisciplinary Team Approach
Can MedEd Encourage Specialists to Form TMA Teams? Tiny clots which form in the body’s small blood vessels - in brief,…
aHUS Diagnosis Process-First Report
The first report on what 227 aHUS patients from around the world told us about their aHUS diagnosis experience and their…
Tweet challenge for aHUS awareness
Research has shown that around 2 million tweets are made on Twitter each day. They are shared by around 600 thousand…
2021 FAQs – FACTS about Atypical HUS
aHUS Awareness Day 2021 - Answers to FAQs Finding information about any rare disease is challenging, and perhaps more so for…
The light and dark world of aHUS
Article No. 453 25 August 2021 Recently Astra Zeneca concluded its purchase of the rare disease business unit, Alexion. $39 billion…